Delamanid (D)

DRUG4 trials

Sponsors

University College, London, Wuhan Pulmonary Hospital, Shanghai Pulmonary Hospital, Shanghai, China, WestVac Biopharma Co., Ltd.

Conditions

Drug-Susceptible Pulmonary TuberculosisEfficacy and SafetyMultidrug Resistant Pulmonary TuberculosisPulmonary TuberculosisRifampicin-resistant TuberculosisTuberculosisTuberculosis, Pulmonary

Phase 2

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

RecruitingNCT06114628

University College, LondonPulmonary Tuberculosis

Start: 2024-01-09End: 2027-08-11Target: 2500Updated: 2025-10-06

Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis

Not yet recruitingNCT07129629

Shanghai Pulmonary Hospital, Shanghai, ChinaDrug-Susceptible Pulmonary Tuberculosis, Tuberculosis, Pulmonary

Start: 2025-08-20End: 2027-12-31Target: 45Updated: 2025-08-19

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

RecruitingNCT07170800

WestVac Biopharma Co., Ltd.Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis, Tuberculosis

Start: 2025-09-19End: 2026-09-04Target: 60Updated: 2026-01-30

Unknown Phase

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

Not yet recruitingNCT07126639

Wuhan Pulmonary HospitalEfficacy and Safety

Start: 2025-09-01End: 2028-09-30Target: 200Updated: 2025-08-17